Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G/A for Sage Therapeutics, Inc. Common Stock (SAGE).
- Disclosed ownership: 1.6%.
- Date of event: 28 Feb 2025.
MORGAN STANLEY - 28 Feb 2025 SCHEDULE 13G/A Report for Sage Therapeutics, Inc. Common Stock (SAGE)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Security
- Sage Therapeutics, Inc. Common Stock
- Symbol
- SAGE
- Shares outstanding
- 63,271,063 shares
- Disclosed Ownership
- 1,012,337 shares
- Ownership
- 1.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 06 Mar 2025, 16:28:17 UTC
- Date of event
- 28 Feb 2025
- Previous filing
- 05 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 1.6% ownership in Sage Therapeutics, Inc. Common Stock (SAGE) on 28 Feb 2025."
What Changed
- Previous schedule filing date: 05 Feb 2025.
- Current filing was accepted on 06 Mar 2025, 16:28.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 1.6% | 1,012,337 | 0 | 921,709 | Christopher O'Hara | Authorized Signatory, Morgan Stanley | |
| Morgan Stanley & Co. LLC | 0.3% | 172,743 | 0 | 172,743 | Christopher O'Hara | Authorized Signatory, Morgan Stanley & Co. LLC |